Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WBRT plus capecitabine versus WBRT alone for newly diagnosed brain metastases from breast cancer
2008-007349-30Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine in breast cancer and brain metastases (2 arms), sponsored by Roche. Primary endpoint: Best objective CNS response rate. Started Mar 2009; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on 2008-007349-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007349-30.